Results 151 to 160 of about 4,485 (161)

Insulin Detemir

Drugs, 2013
Gillian M Keating
exaly  

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2005
T Haak, W Waldhäusl, A Tiengo
exaly  

Insulin Detemir Use Is Associated With Higher Occurrence of Hypoglycemia in Hospitalized Patients With Hypoalbuminemia

Diabetes Care, 2018
Irit Hochberg
exaly  

Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart

Diabetes Care, 2003
Philippe Vague, Jean-Louis Selam, Hanne Haahr   +2 more
exaly  

Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE

Advances in Therapy, 2009
Michel Marre, Hélène Hanaire, Pierre Fontaine   +2 more
exaly  

An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)

Expert Opinion on Pharmacotherapy, 2008
Athena Philis-Tsimikas
exaly  

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

Diabetes, Obesity and Metabolism, 2005
P Vague, I de Leeuw, J W F Elte
exaly  

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

Diabetes, Obesity and Metabolism, 2010
Stephan D Bouman, Jeppe Sturis, Peter Kurtzhals   +2 more
exaly  

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

Diabetologia, 2004
Pierre Fontaine, M A Gall
exaly  

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients—The PREDICTIVE™ BMI clinical trial1

Diabetic Medicine, 2008
exaly